Drug Profile
Research programme: hepatitis therapeutics - InterMune
Latest Information Update: 26 Sep 2019
Price :
$50
*
At a glance
- Originator InterMune
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis
Most Recent Events
- 13 Apr 2010 Discontinued - Preclinical for Hepatitis in USA (unspecified route)
- 31 Dec 2008 This programme is still in active development